Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 78c, Beats on Revenue; Offers FY23 Revenue Guidance

Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.49, $0.78 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $100.37 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2023 revenue of $390-395 million, versus the consensus of $389.1 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
• AeroVironment (AVAV) Tops Q4 EPS by 36c